Pasireotide (SOM230): Development, mechanism of action and potential applications

Adams, 2004, Inhibition of endothelial proliferation by the somatostatin analogue SOM230, Clin. Endocrinol. (Oxf.), 61, 431, 10.1111/j.1365-2265.2004.02098.x

Ambrosi, 1990, Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion, J. Endocrinol. Invest., 13, 257, 10.1007/BF03349555

Batista, 2006, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas, J. Clin. Endocrinol. Metab., 91, 4482, 10.1210/jc.2006-1245

Becker, 2007, Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study, Hepatology, 45, 9, 10.1002/hep.21468

Boscaro, M., Petersenn, S., Atkinson, A.B., Bertherat, J., Findling, J., Snyder, P., McBride, K., Reincke, M., Ludlam, W., Gao, B., Melmed, S., Freda, P., Frohman, L., Grossman, A., Biller, B.M.K., Glusman, J.E., 2006. Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: preliminary safety and efficacy results of a Phase II study. Presented at ENDO 2006 abst OR9-1.

Bruns, 2002, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, Eur. J. Endocrinol., 146, 707, 10.1530/eje.0.1460707

Cebon, 2006, Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide, Br. J. Cancer, 95, 853, 10.1038/sj.bjc.6603325

Comi, 2006, Octreotide: a 15-year update, Endocrinologist, 16, 86, 10.1097/01.ten.0000203247.66715.c0

Cozzi, 2006, Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage, J. Clin. Endocrinol. Metab., 91, 1397, 10.1210/jc.2005-2347

Farrall, A., Glusman, J.E., Buchelt, A., Gao, B., Petersenn, S., 2007. Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: results from a Phase II trial. Presented at ENDO 2007 abst OR53-4.

Fedele, 2007, SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas, Clin. Cancer Res., 13, 2738, 10.1158/1078-0432.CCR-06-2505

Freda, 2005, Long-acting somatostatin analog therapy of acromegaly: a meta-analysis, J. Clin. Endocrinol. Metab., 90, 4465, 10.1210/jc.2005-0260

Hofland, 2003, The pathophysiological consequences of somatostatin receptor internalization and resistance, Endocr. Rev., 24, 28, 10.1210/er.2000-0001

Hofland, 2005, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5, Eur. J. Endocrinol., 152, 645, 10.1530/eje.1.01876

Kulaksiz, 2002, Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies, Gut, 50, 52, 10.1136/gut.50.1.52

Kvols, 2006, Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors, Anticancer Drugs, 17, 601, 10.1097/01.cad.0000210335.95828.ed

Kvols, 2006, Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study, J. Clin. Oncol., 24, 198s, 10.1200/jco.2006.24.18_suppl.4082

Lamberts, 1989, The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease, Acta Endocrinol. (Copenh.), 120, 760, 10.1530/acta.0.1200760

Lancranjan, 1999, Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group, Pituitary, 1, 105, 10.1023/A:1009980404404

Lattuada, 2007, Inhibitory effect of pasireotide and octreotide on lymphocyte activation, J. Neuroimmunol., 182, 153, 10.1016/j.jneuroim.2006.10.007

Ma, 2005, Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly, Clin. Pharmacol. Ther., 78, 69, 10.1016/j.clpt.2005.04.003

Melmed, 2006, Medical progress: acromegaly, N. Engl. J. Med., 355, 2558, 10.1056/NEJMra062453

Mercado, 2007, A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR((R)) (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly, Clin. Endocrinol. (Oxf.), 66, 859, 10.1111/j.1365-2265.2007.02825.x

Mitsiades, 2006, Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer, Anticancer Res., 26, 3693

Modlin, 2006, Therapeutic options for gastrointestinal carcinoids, Clin. Gastroenterol. Hepatol., 4, 526, 10.1016/j.cgh.2005.12.008

Norrelund, 2002, Ghrelin immunoreactivity in human plasma is suppressed by somatostatin, Clin. Endocrinol. (Oxf.), 57, 539, 10.1046/j.1365-2265.2002.01649.x

Schmid, 2004, Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors, Neuroendocrinology, 80, 47, 10.1159/000080741

Schmid, 2005, Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats, J. Endocrinol. Invest., 28, 28

Schmid, H.A., Brueggen, J., Guitard, P., 2007. Effects of a long acting release formulation of pasireotide (SOM230) on hormone secretion in rats. Presented at ENDO 2007 abst P3-337.

Silva, 2005, Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats, Eur. J. Endocrinol., 153, R7, 10.1530/eje.1.01998

Silva, 2005, Regulation of ghrelin secretion by somatostatin analogs in rats, Eur. J. Endocrinol., 152, 887, 10.1530/eje.1.01914

Strowski, 2002, Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells, Neuroendocrinology, 75, 339, 10.1159/000059430

Van Der Hoek, 2004, A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients, J. Clin. Endocrinol. Metab., 89, 638, 10.1210/jc.2003-031052

Van Der Hoek, 2005, The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients, Clin. Endocrinol. (Oxf.), 63, 176, 10.1111/j.1365-2265.2005.02322.x

Van Der Hoek, 2005, Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells, Am. J. Physiol. Endocrinol. Metab., 289, E278, 10.1152/ajpendo.00004.2005

Weckbecker, 2002, SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs, Endocrinology, 143, 4123, 10.1210/en.2002-220219